AIM: To investigate the effectiveness of gamma oryzanol (γ-oryzanol) in managing hyperglycaemia, oxidative stress, inflammation, and dyslipidaemia in a rodent model of diabetes mellitus.
METHODOLOGY: The review was conducted by searching PubMed, ScienceDirect, Scopus, and Web of Science for articles published from inception to July 12, 2025, with the terms (Gamma-oryzanol OR γ-oryzanol OR Oryzanol OR Cycloartenyl ferulate OR Gammariza) AND (Diabetes mellitus OR Type 2 diabetes mellitus OR hyperglycemia OR oxidative stress OR inflammation OR dyslipidaemia). The review included only articles that used rat and mouse models of diabetes mellitus and γ-oryzanol as treatments; articles that did not meet these criteria were excluded. A total of nine articles were identified, encompassing a total population of 394 rodents. SyCLE's risk of bias tool was used to assess the methodological quality of the studies.
RESULTS: Out of 1,989 records initially identified through the systematic search, nine studies met the eligibility criteria. All included studies were assessed to have an unclear to low risk of bias. The synthesised findings indicate that γ-oryzanol (γ-ORZ) exerts beneficial effects on glycaemic control by enhancing insulin secretion and sensitivity, as well as by reducing fasting blood glucose (FBG) levels. Additionally, γ-ORZ demonstrates antioxidant activity by elevating endogenous antioxidant enzyme levels and decreasing oxidative stress markers. Its lipid-modulatory effects include the elevation of beneficial lipid fractions and the reduction of atherogenic lipids, thereby alleviating diabetic dyslipidaemia. Moreover, γ-ORZ exhibits anti-inflammatory properties through the downregulation of proinflammatory biomarkers. Despite these promising results in preclinical models, further high-quality investigations, particularly well-designed clinical trials, are essential to validate these findings and support the potential integration of γ-ORZ into diabetes management strategies.
CONCLUSION: Most included studies reported that γ-ORZ positively affected hyperglycaemia, oxidative stress, dyslipidaemia, and inflammation under diabetic conditions. Further research, particularly rigorously designed clinical trials, is strongly recommended to confirm and translate these preclinical findings into clinical practice.
METHODS: Two experiments examined agreement between AEPs and behavioral thresholds. Experiment 1 (n = 8 ears) used LS CE-Chirp stimuli at 33.3 stimuli/second. Experiment 2 (n = 12 ears) used 1 kHz tone burst stimuli and examined three conditions: behavioral thresholds at 33.3 stimuli/second (Experiment 2a), behavioral thresholds at 1.0 stimuli/second (Experiment 2b), and standard 1 kHz pure tone audiometry (Experiment 2c). Different adult groups (≥18 years) were recruited for each experiment. Behavioral thresholds were obtained via the Hughson-Westlake method. Thresholds were compared using Wilcoxon signed-rank tests.
RESULTS: Agreement patterns varied systematically with stimulus characteristics. For LS CE-Chirp stimuli at 33.3 stimuli/second, ABR thresholds showed significantly better agreement with behavioral thresholds than CAEP thresholds (p < 0.05). For 1 kHz tone burst stimuli at 33.3 stimuli/second, no significant difference was observed between ABR and CAEP agreement with behavioral thresholds (p > 0.05). However, at 1.0 stimuli/second, CAEP thresholds demonstrated significantly better agreement with behavioral thresholds than ABR thresholds (p < 0.05). Both ABR and CAEP thresholds showed comparable agreement with clinical 1 kHz pure tone audiometry thresholds (p > 0.05).
CONCLUSION: These preliminary findings demonstrate that both stimulus type and presentation rate influence threshold estimation, with slower rates favoring cortical-behavioral agreement and faster rates favoring brainstem-behavioral agreement. These context-dependent patterns may guide measurement strategies and support their use in the identification of auditory dysfunction. Further research with larger samples is needed to validate these findings and establish their clinical applicability.
METHODS: The cross-sectional study enrolled 156 participants, with 114 confirmed clinical dengue cases and 42 healthy controls. Serological profiling (NS1, anti-DENV IgM, and anti-DENV IgG), estimation of serum acute-phase reactants, clinico-laboratory parameters, and viral load were performed to classify dengue patients under dengue with warning signs (DWS+, n = 35), dengue without warning signs (DWS-, n = 74), and severe dengue (n = 5) (based on varying grades of severity) in accordance with the 2009 WHO guidelines. Measurement of complement factors, i.e., C1 inhibitor (C1Inh) (n = 145), C1q (n = 152), C2 (n = 146), C3a (n = 153), C3b (n = 152), mannose-binding lectin (MBL) (n = 151), C5a (n = 150), and soluble complement receptor 1 (sCR1, also designated as sCD35) (n = 139), was performed using commercial ELISA, and their concentrations were correlated with acute-phase reactants, clinical laboratory parameters, grades of dengue severity, and platelet levels.
RESULTS: Our analysis showed a significant alteration in early classical complement proteins, C1Inh, C1q, and C2. The levels of downstream factors and sCR1 remained largely unchanged across both the grades of dengue severity and primary/secondary dengue cohorts. Univariate analysis revealed NS1 positivity, IgG positivity, age, urea, and sCR1 as factors associated with disease severity. Our multivariate analysis showed sCR1 as the only independent predictor that correlated negatively with dengue severity. Every unit increase of sCR1 was associated with 22% reduced odds of dengue severity. Platelet counts showed a negative association with red cell distribution width (RDW) and basophils and a strong positive correlation with serum uric acid levels.
CONCLUSIONS: Our findings show that aberrant complement activation and levels of sCR1 could attribute to varying grades of dengue severity. Given its inverse association, the levels of sCR1 could likely render early prediction of dengue disease severity. The role of sCR1 in complement-mediated pathogenesis in dengue remains a gray area of investigation.